Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The way I interpret it is that there results would have been higher, if they weren't focusing on shifting the biz focus to higher margin brand products. I think they were willing to accept a lower quarter of results, expecting better results down the road post shift. That's how I see it currently. What do you think?
Pan O War, what does that paragraph mean exactly?
I think they have managed to shift the baseline of how they are operating, their focus, production capacity and how/where they are selling. I think growth will pick-up from here:
"In the Company’s March 2019 quarterly update, it communicated its strategic decision to
reduce focus on lower margin private label business in the US to enable increased capacity
for expected future growth of higher margin branded products and provide the ability to capture
further market share. Excluding this private label business, normalised revenue growth for Q2
FY2019 would have been reported at 38% on PCP (normalised revenue growth for H1 FY2019
would have been reported at 34% on PCP)."
Excellent - love that we are a global player, and not just USA.
Elixinol partners with PharmaCare to release CBD products
ASX Announcement 29 July 2019
https://www.elixinolglobal.com/site/PDF/2557_0/ElixinolpartnerswithPharmaCare
Video review of Elixinol Products: insert-text-here
Added with size today.
CBD, some companies are doing it well....
Elixinol is one of em.
These cheapies are too good to pass up.
Seems like a stock specific panic on no news. ELLXF makes no claims - so not in the same boat as Curaleaf.
Is this continued drop accelerating from FDA debate hearing and Cura problems earlier this week? Other CBDs have started to hold and reverse. Thoughts on Elixinol’s advantages and challenges?
Video - Paul at Irish Hemp Summit: insert-text-here
Great entry price!
Elixinol Global Ltd. (ELLXF)
2.68 ? -0.138 (-4.90%)
Volume: 230,755 @07/23/19 3:58:41 PM EDT
Bid Ask Day's Range
2.65 2.72 2.64 - 2.845
ELLXF Detailed Quote
Elixinol continues to build Leadership team:
insert-text-here
Elixinol Is A Uniquely Positioned Legitimate Threat In The Cannabis And CBD Space
https://seekingalpha.com/article/4276302-elixinol-uniquely-positioned-legitimate-threat-cannabis-cbd-space?dr=1&fbclid=IwAR0qoe1qoPWVbdvthHvx88d5-ngAi2Y0yfB0rqZzq2VYbmYVhVqpna9_FD0
Elixinol acquires global IP rights for microencapsulation
technology - provides benefits to many sectors including food,
beverage and nutraceuticals
insert-text-here
Welcome aboard. Good company. This also trades on the ASX - you can follow delayed prices here: insert-text-here
Thousands Of Comments Urge FDA To Allow CBD In Foods And Supplements
insert-text-here
Yes the tide is turning!
Looks like it did spike to $4.18 on ASX when news came out and then closed down a nickel, at $3.95.
Huge news, Pan O War. Should soar tonight on ASX.
Nunyara Manufacturing License Granted:
insert-text-here
ELLXF: Elixinol restructures board ahead of international push
https://www.businessnewsaus.com.au/articles/elixinol-restructures-board-ahead-of-international-push.html
Written on the 16 July 2019 by Paris Faint
There's been a reshuffle at the top of Australia's largest cannabis company.
Elixinol Global (ASX: EXL) has announced changes to both its executive team and board ahead of a crucial period of expansion.
Stratos Karousos has taken the reigns as CEO, replacing co-founder Paul Benhaim (pictured) who will transition to the role of chief innovation officer.
Both Karousos and Benhaim will sit on the board as Elixinol focuses on expanding its Sydney-based global executive office and increasing its regional support.
Non-executive chairman Andrew Duff says the leadership changes and expansion is timely, given the company's fast-growing scale and status as the country's largest cannabis player.
"These group structure changes will better enable Elixinol Global to capitalise on the significant industry opportunity, and reflect Elixinol Global's continued and exciting growth," says Duff.
"The company is now of a scale that coordinated global resources are necessary to leverage insights and create efficiencies."
Elixinol Global was formed in January 2018 when Colorado-based Elixinol LLC joined forces with Hemp Foods Australia to form a new worldwide brand and launch an IPO.
Under the company structure, Hemp Foods Australia is the manufacturer and distributor of hemp food products and skin care, while Elixinol LLC is the bulk and retail provider of hemp-based cannabidiol (CBD) dietary supplements and topical products.
Although Benhaim is no longer at the helm as CEO, he is excited to move back into a hands-on role.
"I'm delighted the company is moving to its next phase of growth. My new role frees me up to focus on my passion for innovation and product development and the company will benefit from Stratos' commercial and business process focus," he says.
Following Elixinol's recent successful $50 million capital raising, Karousos says the company will continue to tackle the hemp-derived CBD market, particularly in the United States.
"Elixinol Global currently has a broad business, both geographically and by product line," he says.
"The plan is to critically review where we want to focus our efforts in the near-term and prioritise areas with the greatest potential.
"We believe the opportunity in the global CBD market, in particular the US, is substantial."
At the time of writing (10:24am AEST), EXL shares are trading at $4.10.
Never miss a news update, subscribe here. Follow us on Facebook, LinkedIn, Instagram and Twitter.
FDA Comment Period ends tonight at midnight: insert-text-here
Not today. Hopefully soon!
Elixinol announces Leadership and Group Structure Update
https://www.elixinolglobal.com/site/PDF/2519_0/LeadershipandGroupStructureupdate
U.S. CBD Sales to Grow an Average of 107% Annually Through 2023: https://www.fool.com/investing/2019/07/14/us-cbd-sales-to-grow-an-average-of-107-annually-th.aspx
FDA Says It Is Speeding Up The CBD Regulation Process
insert-text-here
FDA to provide update on CBD review by late summer or fall:
insert-text-here
Looking like the $3's will hold again today (looking at ASX). We are def in a new up-trend!
ELLXF Quarterly Report due end of July.
Looking really good!
I think we could break + hold the $3s today!
Level 2s looking great!
Up 7.5% on ASX last night.
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1174
|
Created
|
09/18/18
|
Type
|
Free
|
Moderators |
50 Pitt Street,
Level 6
Sydney, NSW 2000
Australia
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |